Wyeth Alzheimer’s Drug Gets Extra Patent Life Under Court Ruling
Executive Summary
Wyeth's Alzheimer's drug bapineuzumab won an additional eight months of patent coverage under a federal court ruling that found the U.S. Patent and Trademark Office had misinterpreted a law governing agency delays in processing patent applications
You may also be interested in...
Pfizer/J&J Alzheimer's Drug Should Get Longer Patent Life, Appeals Court Says
An appeals court ruled that the Patent and Trademark Office had miscalculated the patent term extension owed to Pfizer and Johnson & Johnson for delays in prosecuting the patent on the investigational Alzheimer's drug bapineuzumab
Pfizer/J&J Alzheimer's Drug Should Get Longer Patent Life, Appeals Court Says
An appeals court ruled that the Patent and Trademark Office had miscalculated the patent term extension owed to Pfizer and Johnson & Johnson for delays in prosecuting the patent on the investigational Alzheimer's drug bapineuzumab